WallStreetZenWallStreetZen

NYSEMKT: PLX
Protalix Biotherapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their PLX stock forecasts and price targets.

Forecast return on equity

Is PLX forecast to generate an efficient return?

Company
185.58%
Industry
118.06%
Market
270.29%
PLX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PLX forecast to generate an efficient return on assets?

Company
117.99%
Industry
36.52%
PLX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PLX earnings per share forecast

What is PLX's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.13+64.13%
Avg 2 year Forecast
$0.55+588.13%
Avg 3 year Forecast
$1.16+1,351.88%
PLX's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

PLX revenue forecast

What is PLX's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$61.2M-1.27%
Avg 2 year Forecast
$107.5M+73.53%
Avg 3 year Forecast
$163.2M+163.46%
PLX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PLX earnings growth forecast

How is PLX forecast to perform vs Biotechnology companies and vs the US market?

Company
176.02%
Industry
40.5%
Market
100.43%
PLX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
PLX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
PLX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

PLX revenue growth forecast

How is PLX forecast to perform vs Biotechnology companies and vs the US market?

Company
33.49%
Industry
288.79%
Market
58.75%
PLX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PLX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PLX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PLX$2.37N/AN/A
NTHI$9.67N/AN/A
OBIO$3.61$14.00+287.81%Strong Buy
EPRX$5.44$11.50+111.40%Strong Buy
MDWD$18.07$31.00+71.56%Buy
View Top Biotech Stocks

Protalix Biotherapeutics Stock Forecast FAQ

What is PLX's earnings growth forecast for 2025-2027?

(NYSEMKT: PLX) Protalix Biotherapeutics's forecast annual earnings growth rate of 176.02% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 40.5%, and it is also forecast to beat the US market's average forecast earnings growth rate of 100.43%.

Protalix Biotherapeutics's earnings in 2025 is $6,275,000.On average, 3 Wall Street analysts forecast PLX's earnings for 2025 to be $10,468,827, with the lowest PLX earnings forecast at $3,906,874, and the highest PLX earnings forecast at $17,580,931. On average, 3 Wall Street analysts forecast PLX's earnings for 2026 to be $43,892,529, with the lowest PLX earnings forecast at $27,348,115, and the highest PLX earnings forecast at $61,951,853.

In 2027, PLX is forecast to generate $92,608,852 in earnings, with the lowest earnings forecast at $89,858,094 and the highest earnings forecast at $96,276,529.

If you're new to stock investing, here's how to buy Protalix Biotherapeutics stock.

What is PLX's revenue growth forecast for 2025-2027?

(NYSEMKT: PLX) Protalix Biotherapeutics's forecast annual revenue growth rate of 33.49% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 288.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.75%.

Protalix Biotherapeutics's revenue in 2025 is $61,948,000.On average, 3 Wall Street analysts forecast PLX's revenue for 2025 to be $4,876,416,153, with the lowest PLX revenue forecast at $4,625,818,116, and the highest PLX revenue forecast at $5,182,826,671. On average, 3 Wall Street analysts forecast PLX's revenue for 2026 to be $8,571,202,363, with the lowest PLX revenue forecast at $7,299,076,468, and the highest PLX revenue forecast at $10,001,596,506.

In 2027, PLX is forecast to generate $13,013,078,489 in revenue, with the lowest revenue forecast at $12,626,377,731 and the highest revenue forecast at $13,528,147,952.

What is PLX's forecast return on assets (ROA) for 2025-2027?

(NYSEMKT: PLX) forecast ROA is 117.99%, which is higher than the forecast US Biotechnology industry average of 36.52%.

What is PLX's Earnings Per Share (EPS) forecast for 2025-2027?

(NYSEMKT: PLX) Protalix Biotherapeutics's current Earnings Per Share (EPS) is $0.08. On average, analysts forecast that PLX's EPS will be $0.13 for 2025, with the lowest EPS forecast at $0.05, and the highest EPS forecast at $0.22. On average, analysts forecast that PLX's EPS will be $0.55 for 2026, with the lowest EPS forecast at $0.34, and the highest EPS forecast at $0.78. In 2027, PLX's EPS is forecast to hit $1.16 (min: $1.13, max: $1.21).

What is PLX's forecast return on equity (ROE) for 2025-2027?

(NYSEMKT: PLX) forecast ROE is 185.58%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.